This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.
Subjects who voluntarily participate in this study and sign the informed consent form.
Age from 18 to 70, male or female.
Histopathologically/cytologically confirmed or clinically diagnosed with hepatocellular carcinoma (HCC).
At least one measurable lesion based on RECIST v1.1.
Known intrahepatic cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma.
Other malignancies within the past 5 years or concurrent malignancy.
Known history of severe hypersensitivity reaction to any monoclonal antibody.
Previous or current central nervous system metastases.